{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:17:58Z","timestamp":1782937078338,"version":"3.54.5"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold><jats:italic>Phe508del<\/jats:italic> is the most common cystic fibrosis transmembrane conductance regulator (CFTR) gene variant that results in the recessive genetic disorder cystic fibrosis (CF). The recent development of highly effective CFTR modulator therapies has led to significant health improvements in individuals with this mutation. While numerous animal models of CF exist, few have a CFTR mutation that is amenable to the triple combination therapy elexacaftor-tezacaftor-ivacaftor (ETI).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> To determine the responsiveness of <jats:italic>Phe508del<\/jats:italic> rats to ETI, a baseline nasal potential difference was measured. Subsequently, they received ETI daily for 14\u00a0days, after which post-treatment nasal potential difference, lung mechanics (via flexiVent) and lung ventilation (via X-ray Velocimetry) were assessed.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Chloride ion transport in nasal airways was restored in <jats:italic>Phe508del<\/jats:italic> rats treated with ETI, but neither lung mechanics nor ventilation were significantly altered.<\/jats:p><jats:p><jats:bold>Discussion:<\/jats:bold> These findings validate the usefulness of this rat model for future investigations of modulator therapy in CF.<\/jats:p>","DOI":"10.3389\/fphar.2024.1362325","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T04:56:35Z","timestamp":1710305795000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Effect of elexacaftor-tezacaftor-ivacaftor on nasal potential difference and lung function in Phe508del rats"],"prefix":"10.3389","volume":"15","author":[{"given":"Nicole","family":"Reyne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Cmielewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"McCarron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Schneider-Futschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Eikelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piraveen","family":"Pirakalathanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Donnelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"eS8","DOI":"10.1016\/S0929-693X(20)30044-0","article-title":"CFTR gene variants, epidemiology and molecular pathology","volume":"27","author":"Bareil","year":"2020","journal-title":"Arch. Pediatr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12890-016-0339-5","article-title":"Cystic fibrosis lung environment and Pseudomonas aeruginosa infection","volume":"16","author":"Bhagirath","year":"2016","journal-title":"BMC Pulm. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1164\/rccm.202002-0369OC","article-title":"Ivacaftor reverses airway mucus abnormalities in a rat model harboring a humanized G551D-CFTR","volume":"202","author":"Birket","year":"2020","journal-title":"Am. J. Respir. Crit. care Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/ame2.12091","article-title":"Characterization of two rat models of cystic fibrosis\u2014KO and F508del CFTR\u2014generated by Crispr\u2010Cas9","volume":"2","author":"Dreano","year":"2019","journal-title":"Animal models Exp. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1513\/AnnalsATS.201902-122OC","article-title":"Ivacaftor is associated with reduced lung infection by key cystic fibrosis pathogens. A cohort study using national registry data","volume":"16","author":"Frost","year":"2019","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B6","doi-asserted-by":"publisher","first-page":"102262","DOI":"10.1016\/j.coph.2022.102262","article-title":"The changing landscape of the cystic fibrosis lung environment: from the perspective of Pseudomonas aeruginosa","volume":"65","author":"Greenwald","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"102235","DOI":"10.1016\/j.coph.2022.102235","article-title":"Animal models of cystic fibrosis in the era of highly effective modulator therapies","volume":"64","author":"Grubb","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.paed.2019.01.011","article-title":"Modulator therapies for cystic fibrosis","volume":"29","author":"Haq","year":"2019","journal-title":"Paediatr. Child Health"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am. J. Respir. Crit. care Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.ajpath.2020.01.009","article-title":"Phenotypic characterization and comparison of cystic fibrosis Rat models generated using CRISPR\/Cas9 gene editing","volume":"190","author":"McCarron","year":"2020","journal-title":"Am. J. pathology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jcf.2021.02.003","article-title":"PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy","volume":"20","author":"Nichols","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1177\/0271678X20943823","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research*","volume":"40","author":"Percie du Sert","year":"2020","journal-title":"J. Cereb. Blood Flow Metabolism"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.1038\/s41598-019-42404-6","article-title":"Novel, rare and common pathogenic variants in the CFTR gene screened by high-throughput sequencing technology and predicted by in silico tools","volume":"9","author":"Pereira","year":"2019","journal-title":"Sci. Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/b98882","article-title":"Linear and nonlinear mixed effects models","volume":"3","author":"Pinheiro","year":"2007","journal-title":"R. package version"},{"key":"B19","volume-title":"A language and environment for statistical computing","year":"2019"},{"key":"B20","doi-asserted-by":"publisher","first-page":"682299","DOI":"10.3389\/fphar.2021.682299","article-title":"Single-dose lentiviral mediated gene therapy recovers CFTR function in cystic fibrosis knockout rats","volume":"12","author":"Reyne","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"eaau7531","DOI":"10.1126\/scitranslmed.aau7531","article-title":"In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis","volume":"11","author":"Sun","year":"2019","journal-title":"Sci. Transl. Med."}],"updated-by":[{"DOI":"10.3389\/fphar.2024.1428213","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1362325\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T09:22:34Z","timestamp":1716801754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1362325\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,13]]},"references-count":21,"alternative-id":["10.3389\/fphar.2024.1362325"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1362325","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fphar.2024.1428213","asserted-by":"object"}]},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,13]]},"article-number":"1362325"}}